Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
暂无分享,去创建一个
H. Kantarjian | J. Cortes | S. Verstovsek | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | N. Pemmaraju | Xuemei Wang | S. Pierce | K. Newberry | K. Sasaki | Lingsha Zhou
[1] J. Dipersio,et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I , 2013, Haematologica.
[2] R. Mesa,et al. Therapy for myeloproliferative neoplasms: when, which agent, and how? , 2014, Hematology. American Society of Hematology. Education Program.
[3] H. Kantarjian,et al. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. , 2014, Leukemia research.
[4] J. Mascarenhas. Rationale for combination therapy in myelofibrosis. , 2014, Best practice & research. Clinical haematology.
[5] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.
[6] J. Dipersio,et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I , 2013, Haematologica.
[7] M. Cazzola,et al. Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence , 2013 .
[8] M. Konopleva,et al. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. , 2013, Leukemia research.
[9] D. Chaussabel,et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. , 2013, Blood.
[10] J. Maciejewski,et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. , 2012, Blood.
[11] M. Kaminski,et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.
[12] M. Cazzola,et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.
[13] H. Kohrt,et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia , 2012, Leukemia.
[14] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[15] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[16] N. Chiorazzi,et al. Evidence for Allelic Exclusion of p53 within Single Sorted Human B Cells , 2011 .
[17] M. Konopleva,et al. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) , 2011 .
[18] T. Barbui,et al. What are RBC-transfusion-dependence and -independence? , 2011, Leukemia research.
[19] M. Tallman,et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. , 2010, Blood.
[20] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[21] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[22] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[23] H. Kantarjian,et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[25] H. Deeg,et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.
[26] H. Kantarjian,et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.
[27] H. Kantarjian,et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia , 2006, Cancer.
[28] R. McClure,et al. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.
[29] A. Tefferi. Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. D. van der Walt,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. , 2005, Haematologica.
[31] J. Desimone. The evolving role of DNA demethylating agents in the treatment of sickle cell disease and thalassemia. , 2004, Seminars in hematology.
[32] J. Spivak. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. , 2004, Seminars in hematology.
[33] M. Le Bousse-Kerdilès,et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Dalgleish,et al. Thalidomide analogs as emerging anti-cancer drugs , 2003, Anti-cancer drugs.
[35] D. Steensma,et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. , 2003, Blood.